Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Rodman & Renshaw Conference 2015
36 slides from Aethlon Medical's conference presentation, Sep 10, 2015
Slide 1: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ system, t
Slide 2: Aethlon Medical, Rodman & Renshaw Conference
A e thlon Medical, Inc . Rodman & Renshaw Conference September 10, 2015 Jim Joyce Chairman, CEO
Slide 3: Affinity Biofiltration Devices to Treat Life-Threatening Diseases
AFFINITY BIOFILTRATION DEVICES TO TREAT LIFE - THREATENING DISEASES
Slide 4: Save Lives
SAVE LIVES ww
Slide 5: Aethlon Details
A e thlon Details • Clinical - stage Therapeutic Organization • Headquartered in San Diego, California • Nasdaq Capital Market: “AEMD” • Market Value: ~ $60 million
Slide 6: Aethlon Technology Highlights
A e thlon Technology Highlights • Expansive Therapeutic Device Platform – Lead product provides clinical pathway into infectious disease and cancer – Advancing a sepsis treatment device through contracts with DARPA
Slide 7: The Aethlon Hemopurifier
The A e thlon Hemopurifier® Single - Use Removal of Viral Pathogens from Circulation
Slide 8: TIME: The Best Inventions of 2014
TIME Deo. 4/Dec. 820g THE 25 BEST INVENTIONS OF 2014
Slide 9: Remarkable Health Advances 2014
11 REMARKABLE HEALTH ADVANCES 3 2014
Slide 10: Rethinking the Treatment of Viral Pathogens
Rethinking the Treatment of Viral Pathogens • Rapid virus elimination – Prior to cell and organ infection – Elution assay q uantifies virus capture • Targets viral structure vs. inhibiting replication – Allows broad - spectrum virus capture • Addresses shed viral proteins – To augment/preserve host
Slide 11: Deployed Within the Global Infrastructure of Dialysis & CRRT Machines
DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
Slide 12: Can the Hemopurifier Improve the Benefit of Drug Treatment Regimens?
Can the Hemopurifier® Improve the Benefit of Drug Treatment Regimens?
Slide 13: Hepatitis C Virus Safety & Efficacy Observations at Medanta
Hepatitis C Virus (HCV ) Safety & Efficacy Observations Conducted at the Medanta - Medicity Institute
Slide 14: HCV Study Highlights
HCV Study Highlights • Safely Administered in Combination with Interferon - Ribavirin Drug Regimen • Improved Rapid Viral Response (RVR) – 58% RVR vs. 10.35% • Based on IDEAL Study of 3070 HCV patients • Two Patients Undetectable at Day Seven • 300 Billion Copies of HCV Captured
Slide 15: Can the Hemopurifier Address Viral Pathogens Not Treatable with Drug Therapies?
Can the Hemopurifier® Address Viral Pathogens Not Treatable with Drug Therapies?
Slide 16: The Treatment of Ebola Virus, Frankfurt University Hospital
The Treatment of Ebola Virus Frankfurt University Hospital Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)
Slide 17: Hemopurifier Therapy Administration to a Comatose Ebola Patient
Hemopurifier® therapy administration to a comatose Ebola patient with multiple - organ failure
Slide 18: Dr. Stefan Büttner Holding Hemopurifier After Ebola Treatment
Dr. Stefan Büttner Holding Hemopurifier® After Ebola Treatment
Slide 19: Ebola Treatment Data Presented at American Society of Nephrology
Ebola Treatment Data Presented By Dr. Helmut Geiger American Society of Nephrology Annual Meeting • 6.5 hour Hemopurifier® therapy administration • Pre - treatment viral load: 400,000 copies/ml • Post - treatment viral load: 1,000 copies/ml • 242 million of Ebola viruses captured • Patient recovered
Slide 20: Extracorporeal Virus Elimination for Severe Ebola Virus Disease
Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis • Stefan Bü ttner a Benjamin Koch a Olga Dolnik b Markus Eickmann b Tilo Freiwald a Sarah Rudolf a Jü rgen Engel a Stephan Becker b Claudio Ronco c Helmut Geiger
Slide 21: The Aethlon Hemopurifier: Our Infectious Disease Opportunity
The A e thlon Hemopurifier® Our Infectious Disease Opportunity
Slide 22: Unmet Needs in Infectious Disease
Unmet Needs in Infectious Disease • Antiviral Drug - R esistance – HIV & HCV • Latent Virus Activation – Immune Suppression • Organ Transplants, Sepsis • Bioterror & Pandemic Threats – Leading broad - spectrum countermeasure against known and unknown viruses
Slide 23: Bioterror & Pandemic Validations
BIOTERROR & PANDEMIC VALIDATIONS Ebola Pandemic Influenza West Nile Pox Viruses Lassa Dengue
Slide 24: Currently Approved Human Treatment Protocols
Currently Approved Human Treatment Protocols • U.S. Food and Drug Administration (FDA) – IDE Feasibility Study (10 Patient) • HCV Infected ESRD Patients (Study Initiated) • Single - site at DaVita Med Center Dialysis in Houston • Gateway to Pivotal Studies – Ebola Treatment Protocol • Health Canada
Slide 25: One More Thing
ONE MORE THING ww
Slide 26: The Aethlon Hemopurifier
The A e thlon Hemopurifier®
Slide 27: Save Lives: Cancer
SAVE LIVES CANCER aethion/@)
Slide 28: Tumor-Secreted Exosomes
Tumor - Secreted Exosomes Extracellular Vesicles or Circulating Microvesicles
Slide 29: Extracellular Vesicles: Emerging Targets for Cancer Therapy
May, 2014 Trends in Molecular Medicine "Extracellular Vesicles: Emerging Targets for Cancer Therapy"
Slide 30: Tumor-Secreted Exosomes: A Significant Unmet Medical Need in Cancer
Tumor - Secreted Exosomes A Significant Unmet Medical Need in Cancer • Trigger apoptosis of immune c ells • Contribute to drug and chemotherapy resistance • Promote angiogenesis • Seed the creation and spread of metastasis • Exosome load correlates with stage of cancer
Slide 31: Clinical Progression Objectives
Clinical Progression Objectives 6 - 12 Months • Complete FDA Approved IDE Study – Prepare pivotal study submission • Advance HUD submissions – Disease conditions affecting < 4000 per yr. in the U.S. • Advance Cancer Treatment Programs
Slide 32: Near-Term Corporate Objectives
Near - Term Corporate Objectives Outlined During Quarterly Call on 8/13/15 • Complete Principal Investigator Transition – IDE Study in Houston • Secure Year - 5 DARPA Contract • Initiate New Clinical Collaborations • Initiate Cancer Study at UC Irvine Medical Center • Submit NFL Detect Study (CTE Ta
Slide 33: Near-Term Corporate Objectives: Progress Since
Near - Term Corporate Objectives Outlined During Quarterly Call on 8/13/15 PROGRESS SINCE • Secure Year - 5 DARPA Contract – Received Verbal Confirmation of Contract Renewal • Initiate New Clinical Collaborations – Initiated Chikungunya Virus Capture Study • Initiate Cancer Study at UC Irvine Medica
Slide 34: Affinity Biofiltration Devices to Treat Life-Threatening Diseases
AFFINITY BIOFILTRATION DEVICES TO TREAT LIFE - THREATENING DISEASES
Slide 35: Our Lead Product Provides a Clinical Pathway to Address Infectious Disease & Cancer
OUR LEAD PRODUCT PROVIDES A CLINICAL PATHWAY TO ADDRESS INFECTIOUS DISEASE & CANCER
Slide 36: Save Lives
SAVE LIVES ww